SE9601091L - Use of a protein substance for the binding of steroid-like molecules - Google Patents

Use of a protein substance for the binding of steroid-like molecules

Info

Publication number
SE9601091L
SE9601091L SE9601091A SE9601091A SE9601091L SE 9601091 L SE9601091 L SE 9601091L SE 9601091 A SE9601091 A SE 9601091A SE 9601091 A SE9601091 A SE 9601091A SE 9601091 L SE9601091 L SE 9601091L
Authority
SE
Sweden
Prior art keywords
bile
treatment
steroid
beneficial
injury
Prior art date
Application number
SE9601091A
Other languages
Swedish (sv)
Other versions
SE9601091D0 (en
Inventor
Joyce Carlson
Sabina-Marija Janciauskiene
Original Assignee
Joyce Carlson
Sabina Marija Janciauskiene
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Joyce Carlson, Sabina Marija Janciauskiene filed Critical Joyce Carlson
Priority to SE9601091A priority Critical patent/SE9601091L/en
Publication of SE9601091D0 publication Critical patent/SE9601091D0/en
Priority to EP97914726A priority patent/EP0904102A1/en
Priority to AU21864/97A priority patent/AU2186497A/en
Priority to PCT/SE1997/000465 priority patent/WO1997034628A1/en
Publication of SE9601091L publication Critical patent/SE9601091L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C07K14/8125—Alpha-1-antitrypsin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20—Milk; Whey; Colostrum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)

Abstract

The use of human alpha 1-antitrypsin as a foodstuff or as a medicament, utilizing its capacity to bind steroids and steroid-like substances, and transporting them in biological systems is described. Particularly the direct oral administration of the milk of transgenic animals containing abundant amounts (10-60 g/L) of human alpha 1-AT to reinstate a defect intestinal synthesis or to complement the normal physiological biosynthesis of alpha 1-AT is described. Such treatment will reduce the total body load of bile acids by increasing their gastrointestinal elimination. It is expected to be beneficial for bile acid related diseases such as all cholestatic liver diseases, and bile-reflux gastritis. Such treatment is expected to be particularly beneficial in cases of neonatal cholestasis, as newborns circulate large quantities of hydrophobic bile acids which cause liver injury and may contribute to injury of other tissues. It will be protective in cases where bile acids cause tissue injury such as vasculitis, glomerulonephritis, and inflammatory bowel disease. It will be beneficial against diarrhoea in intestinal bacterial overgrowth and bile acid malabsorption. Increased gastrointestinal elimination of the steroid structure may also reduce the total body load of cholesterol and thus be efficient in the treatment of hyperlipidemia.
SE9601091A 1996-03-21 1996-03-21 Use of a protein substance for the binding of steroid-like molecules SE9601091L (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
SE9601091A SE9601091L (en) 1996-03-21 1996-03-21 Use of a protein substance for the binding of steroid-like molecules
EP97914726A EP0904102A1 (en) 1996-03-21 1997-03-20 Milk of transgenic animals containing human alpha 1-antitrypsin and use of human alpha 1-antitrypsin to treat bile acid related diseases
AU21864/97A AU2186497A (en) 1996-03-21 1997-03-20 Milk of transgenic animals containing human alpha1-antitrypsin and use of human alpha1-antitrypsin to treat bile acid related diseases
PCT/SE1997/000465 WO1997034628A1 (en) 1996-03-21 1997-03-20 Milk of transgenic animals containing human alpha1-antitrypsin and use of human alpha1-antitrypsin to treat bile acid related diseases

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9601091A SE9601091L (en) 1996-03-21 1996-03-21 Use of a protein substance for the binding of steroid-like molecules

Publications (2)

Publication Number Publication Date
SE9601091D0 SE9601091D0 (en) 1996-03-21
SE9601091L true SE9601091L (en) 1997-09-22

Family

ID=20401887

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9601091A SE9601091L (en) 1996-03-21 1996-03-21 Use of a protein substance for the binding of steroid-like molecules

Country Status (4)

Country Link
EP (1) EP0904102A1 (en)
AU (1) AU2186497A (en)
SE (1) SE9601091L (en)
WO (1) WO1997034628A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000030436A1 (en) * 1998-11-19 2000-06-02 Ppl Therapeutics (Scotland) Ltd. Stabilisation of milk from transgenic animals
US7030289B2 (en) 1998-11-19 2006-04-18 Ppl Therapeutics (Scotland) Ltd Stabilization of milk from transgenic animals
EP1150699A4 (en) * 1999-02-01 2004-06-30 John Lezdey Treatment of bladder and gastrointestinal mastocytosis
AUPP971399A0 (en) * 1999-04-12 1999-05-06 Life Therapeutics Limited Separation of plasma components
JPWO2009008120A1 (en) * 2007-07-12 2010-09-02 杉山　雄一 Membrane protein stabilizer and stabilization method
ES2902404T3 (en) 2016-02-22 2022-03-28 Novartis Ag Methods for using fxr agonists.

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873316A (en) * 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5439824A (en) * 1993-05-06 1995-08-08 The United States Of America Increased expression of α-1-antitrypsin in expression vectors through the inclusion of intron II

Also Published As

Publication number Publication date
SE9601091D0 (en) 1996-03-21
AU2186497A (en) 1997-10-10
EP0904102A1 (en) 1999-03-31
WO1997034628A1 (en) 1997-09-25

Similar Documents

Publication Publication Date Title
Morita et al. Resistant proteins alter cecal short-chain fatty acid profiles in rats fed high amylose cornstarch
Schroeder The Ce: Role of Chromium in Mammalian Nutrition
Russel Elemental diets.
NO20063328L (en) Use of a fatty acid composition comprising at least one of EPA and DHA or combinations thereof
Banasiewicz et al. Determination of butyric acid dosage based on clinical and experimental studies–a literature review
WO2008066308A1 (en) Food composition for increasing the satiety and satiation
KR100642080B1 (en) A food composition containing swine placenta extraction for improving menopausal disorder, health foods comprising of it and preparation method thereof
UA78699C2 (en) Use of bile acid or bile salt fatty acid conjugates for decreasing cholesterol blood content, treating fatty liver, hyperglycemia, and diabetes
Bowman et al. Biotin absorption by distal rat intestine
Malyugina et al. The Practicability of the Application of Vitamin D in Combination with Vitamin C for the Improvement of Bone Tissue Metabolism.
Jangra et al. Ameliorative effect of fermentable fibres on adiposity and insulin resistance in C57BL/6 mice fed a high-fat and sucrose diet
SE9601091L (en) Use of a protein substance for the binding of steroid-like molecules
McCollum et al. The" vitamine" hypothesis and deficiency diseases: a study of experimental scurvy
Finkel et al. The effects of a pectin‐supplemented elemental diet in a boy with short gut syndrome
JP4383165B2 (en) Nutritional composition to prevent bacterial overgrowth
Hall et al. Response of the organs of rabbits to feeding during the first days after birth
Verdegem et al. Effect of dietary NSP level and bile acid supplementation on nutrient digestibility and the bile acid metabolism in rainbow trout (Oncorhynchus mykiss)
Chinery et al. Soy polysaccharide in an enteral diet: effects on rat intestinal cell proliferation, morphology and metabolic function
ES2913336T3 (en) Methods of using secretory IgA
Gandarillas et al. The domestic pig (Sus scrofa domestica) as a model for evaluating nutritional and metabolic consequences of bariatric surgery practiced on morbid obese humans
Guilford New ideas for the dietary management of gastrointestinal tract disease
KR100484326B1 (en) Foods containing cocoa component
Hofmann Targeting drugs to the enterohepatic circulation: lessons from bile acids and other endobiotics
CN110710600A (en) Nutritional paste for pet dogs with renal failure and preparation method thereof
Shabbir Psyllium the hidden superfood of all times

Legal Events

Date Code Title Description
NAV Patent application has lapsed